Alto Neuroscience, Inc.
ANRO
$24.63
$0.100.41%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.45% | 15.50% | -10.46% | -13.06% | -35.52% |
| Total Depreciation and Amortization | -7.65% | 34.43% | 49.56% | 76.29% | 51.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.06% | 30.39% | -11.82% | 19.64% | 159.29% |
| Change in Net Operating Assets | 2,021.21% | -53.45% | -9.44% | -1,727.06% | 108.56% |
| Cash from Operations | 11.56% | 15.42% | -17.83% | -50.74% | -12.99% |
| Capital Expenditure | 100.00% | 100.00% | 100.00% | 89.29% | -43.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | 100.00% | 89.29% | -43.75% |
| Total Debt Issued | -- | -40.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 102,659.18% | 128.36% | -100.00% | -99.86% | 68.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 307.80% | 81.98% | 100.00% |
| Cash from Financing | 102,318.37% | -88.38% | 361.97% | -93.22% | -99.89% |
| Foreign Exchange rate Adjustments | -116.67% | 42.86% | 40.00% | -340.00% | 50.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 387.02% | 14.46% | -7.30% | -106.06% | -143.10% |